Cargando…

Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study

OBJECTIVE: To develop a multimarker prognostic score for infective endocarditis (IE). DESIGN: Retrospective case–control. SETTING: Secondary care. Single centre. PARTICIPANTS: 125 patients with definite IE. PRIMARY OUTCOME MEASURES: 90-day and 5-year mortality. RESULTS: Mean age was 62.7±17 years. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Bjurman, Christian, Snygg-Martin, Ulrika, Olaison, Lars, Fu, Michael L X, Hammarsten, Ola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400063/
https://www.ncbi.nlm.nih.gov/pubmed/22798251
http://dx.doi.org/10.1136/bmjopen-2012-000856
_version_ 1782238454824828928
author Bjurman, Christian
Snygg-Martin, Ulrika
Olaison, Lars
Fu, Michael L X
Hammarsten, Ola
author_facet Bjurman, Christian
Snygg-Martin, Ulrika
Olaison, Lars
Fu, Michael L X
Hammarsten, Ola
author_sort Bjurman, Christian
collection PubMed
description OBJECTIVE: To develop a multimarker prognostic score for infective endocarditis (IE). DESIGN: Retrospective case–control. SETTING: Secondary care. Single centre. PARTICIPANTS: 125 patients with definite IE. PRIMARY OUTCOME MEASURES: 90-day and 5-year mortality. RESULTS: Mean age was 62.7±17 years. The 90-day and 5-year mortality was 10.4% and 33.6%, respectively. CysC levels at admission and over 20% increases in CysC levels during 2 weeks of treatment were prognostic for 90-day and 5-year mortality independent of creatinine estimated glomerular filtration rate. In multivariate analyses, CysC (OR 5.42, 95% CI 1.90 to 15.5, p=0.002) and age (OR 1.06, 95% CI 1.02 to 1.10, p=0.002) remained prognostic for 5-year mortality. NT-proBNP, TnT, C reactive protein and interleukin 6 were also linked to prognosis. A composite risk scoring system using levels of CysC, NT-proBNP, age and presence of mitral valve insufficiency was able to separate a high-risk and a low-risk group. CONCLUSIONS: CysC levels at admission and increase in CysC after 2 weeks of treatment were independent prognostic markers for both 90-day and 5-year mortality in patients with IE. A multimarker composite risk scoring system including CysC identified a high-risk group.
format Online
Article
Text
id pubmed-3400063
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BMJ Group
record_format MEDLINE/PubMed
spelling pubmed-34000632012-07-23 Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study Bjurman, Christian Snygg-Martin, Ulrika Olaison, Lars Fu, Michael L X Hammarsten, Ola BMJ Open Cardiovascular Medicine OBJECTIVE: To develop a multimarker prognostic score for infective endocarditis (IE). DESIGN: Retrospective case–control. SETTING: Secondary care. Single centre. PARTICIPANTS: 125 patients with definite IE. PRIMARY OUTCOME MEASURES: 90-day and 5-year mortality. RESULTS: Mean age was 62.7±17 years. The 90-day and 5-year mortality was 10.4% and 33.6%, respectively. CysC levels at admission and over 20% increases in CysC levels during 2 weeks of treatment were prognostic for 90-day and 5-year mortality independent of creatinine estimated glomerular filtration rate. In multivariate analyses, CysC (OR 5.42, 95% CI 1.90 to 15.5, p=0.002) and age (OR 1.06, 95% CI 1.02 to 1.10, p=0.002) remained prognostic for 5-year mortality. NT-proBNP, TnT, C reactive protein and interleukin 6 were also linked to prognosis. A composite risk scoring system using levels of CysC, NT-proBNP, age and presence of mitral valve insufficiency was able to separate a high-risk and a low-risk group. CONCLUSIONS: CysC levels at admission and increase in CysC after 2 weeks of treatment were independent prognostic markers for both 90-day and 5-year mortality in patients with IE. A multimarker composite risk scoring system including CysC identified a high-risk group. BMJ Group 2012-07-12 /pmc/articles/PMC3400063/ /pubmed/22798251 http://dx.doi.org/10.1136/bmjopen-2012-000856 Text en © 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Cardiovascular Medicine
Bjurman, Christian
Snygg-Martin, Ulrika
Olaison, Lars
Fu, Michael L X
Hammarsten, Ola
Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study
title Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study
title_full Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study
title_fullStr Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study
title_full_unstemmed Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study
title_short Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study
title_sort cystatin c in a composite risk score for mortality in patients with infective endocarditis: a cohort study
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400063/
https://www.ncbi.nlm.nih.gov/pubmed/22798251
http://dx.doi.org/10.1136/bmjopen-2012-000856
work_keys_str_mv AT bjurmanchristian cystatincinacompositeriskscoreformortalityinpatientswithinfectiveendocarditisacohortstudy
AT snyggmartinulrika cystatincinacompositeriskscoreformortalityinpatientswithinfectiveendocarditisacohortstudy
AT olaisonlars cystatincinacompositeriskscoreformortalityinpatientswithinfectiveendocarditisacohortstudy
AT fumichaellx cystatincinacompositeriskscoreformortalityinpatientswithinfectiveendocarditisacohortstudy
AT hammarstenola cystatincinacompositeriskscoreformortalityinpatientswithinfectiveendocarditisacohortstudy